REGENERON PHARMACEUTICALS, INC. - FORM 10-K - EX-23.1 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - February 9, 2017

Attached files

file filename
EX-10.24.5 - CREDIT SUISSE TERMINATION AGREEMENT, BY AND BETWEEN CREDIT SUISSE AND REGISTRANT - REGENERON PHARMACEUTICALS, INC.regn-ex_10245xcreditsuisse.htm
10-K - FORM 10-K - REGENERON PHARMACEUTICALS, INC.regn-123116x10k.htm
EX-32 - CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350 - REGENERON PHARMACEUTICALS, INC.regn-ex_32x12312016x10k.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.regn-ex_312x12312016x10k.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.regn-ex_311x12312016x10k.htm
EX-21.1 - SUBSIDIARIES OF REGENERON PHARMACUTICALS, INC. - REGENERON PHARMACEUTICALS, INC.regn-ex_211x12312016x10k.htm
EX-10.35 - PURCHASE AGREEMENT, BY & AMONG BMR-LANDMARK LLC, BMR-LANDMARK IV LLC, & REGN - REGENERON PHARMACEUTICALS, INC.regn-ex_1035xlandmarkpsaex.htm
EX-10.26.3 - MORGAN STANLEY TERMINATION AGREEMENT, BY AND BETWEEN MORGAN STANLEY & REGISTRANT - REGENERON PHARMACEUTICALS, INC.regn-ex_10263xmorganstanle.htm
EX-10.22.4 - CITI TERMINATION AGREEMENT, BY AND BETWEEN CITI AND REGISTRANT - REGENERON PHARMACEUTICALS, INC.regn-ex_10224xcititerminat.htm
EX-10.22.3 - CITI 3RD WARRANT AGREEMENT, BY AND BETWEEN CITI AND REGISTRANT - REGENERON PHARMACEUTICALS, INC.regn-ex_10223xciti3rdwarra.htm
EX-10.20.4 - GOLDMAN SACHS TERMINATION AGREEMENT, BY AND BETWEEN GOLDMAN SACHS AND REGISTRANT - REGENERON PHARMACEUTICALS, INC.regn-ex_10204xgoldmansachs.htm


Exhibit 23.1


CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S‑8 (Nos. 333-61132, 333-97375, 333-119257, 333-151941, 333-169569, 333-174863, 333-196799, and 333-198794) of Regeneron Pharmaceuticals, Inc., of our report dated February 9, 2017 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.


/s/ PricewaterhouseCoopers LLP

Florham Park, New Jersey
February 9, 2017




REGENERON PHARMACEUTICALS, INC. Reports